Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

February 7, 2023

Primary Completion Date

April 11, 2025

Study Completion Date

April 11, 2025

Conditions
Invasive Fungal Disease
Interventions
DRUG

Isavuconazole

This is a single arm study, all enrolled participants will receive the study intervention.

Trial Locations (14)

100044

Peking University People's Hospital, Beijing

200040

Huashan Hospital, Fudan University, Shanghai

201800

Jiading Central Hospital, Shanghai

230001

The First Affiliated Hospital of USTC, Anhui Province Hospital, Hefei

233000

The First Affiliated Hospital of Bengbu Medical College, Bengbu

252000

Liaocheng people's Hospital, Liaocheng

255036

Zibo Central Hospital, Zibo

300020

Institute of Hematology, Chinese Academy of Medical Sciences, Tianjin

310003

The First Affiliated Hospital Zhejiang University, Hangzhou

450003

Henan provincial people's hospital, Zhengzhou

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

510180

Guangzhou First People's Hospital, Guangzhou

510280

ZhuJiang Hospital of Southern Medical University, Guangzhou

522095

Jieyang People's Hospital, Jieyang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05630976 - Cresemba® in Treating Chinese Patients With IFD Caused by Aspergillus Species or Other Filamentous Fungi | Biotech Hunter | Biotech Hunter